Abstract
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
MeSH terms
-
Acetamides / adverse effects*
-
Anemia / blood*
-
Anemia / chemically induced*
-
Anti-Infective Agents / adverse effects*
-
Blood Cell Count
-
Clinical Trials as Topic
-
Hemoglobins / metabolism
-
Humans
-
Linezolid
-
Neutropenia / blood
-
Neutropenia / chemically induced
-
Oxazolidinones / adverse effects*
-
Retrospective Studies
-
Thrombocytopenia / blood
-
Thrombocytopenia / chemically induced
Substances
-
Acetamides
-
Anti-Infective Agents
-
Hemoglobins
-
Oxazolidinones
-
Linezolid